Administration of Jakafi (Ruxolitinib) to Patients with Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial
The goal of this clinical research study is to learn if Jakafi (ruxolitinib) can delay, lower the amount of therapy you may need in the future, or possibly eliminate the need for future therapy in recently diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
Treatment Location: N/A
IRB Review and Approval Date: 03/08/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: